# Kathryn A. Gold

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/kathryn-a-gold/

## Facts

| Field | Value |
| --- | --- |
| Citations | 7,085 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 34 |
| i10-index | 70 |
| Last Known Institution | UC San Diego Health System |
| OpenAlex ID | https://openalex.org/A5038912570 |
| ORCID iD | 0000-0001-5165-4424 |
| Works | 182 |

## Researcher papers

- [Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing](https://scholariq.org/papers/intratumor-heterogeneity-in-localized-lung-adenocarcinomas-delineated-by/)
- [Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial](https://scholariq.org/papers/alectinib-in-alk-positive-crizotinib-resistant-non-small-cell-lung-cancer-a/)
- [Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component](https://scholariq.org/papers/osimertinib-in-pretreated-t790m-positive-advanced-non-small-cell-lung-cancer/)
- [Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer](https://scholariq.org/papers/phase-iii-randomized-trial-of-ipilimumab-plus-etoposide-and-platinum-versus/)
- [Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/small-cell-lung-cancer-version-2-2022-nccn-clinical-practice-guidelines-in/)
- [Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial](https://scholariq.org/papers/activity-and-safety-of-brigatinib-in-alk-rearranged-non-small-cell-lung-cancer/)
- [Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial](https://scholariq.org/papers/pembrolizumab-plus-cetuximab-in-patients-with-recurrent-or-metastatic-head-and/)
- [Eat and Exercise During Radiotherapy or Chemoradiotherapy for Pharyngeal Cancers](https://scholariq.org/papers/eat-and-exercise-during-radiotherapy-or-chemoradiotherapy-for-pharyngeal-cancers/)
- [Relationship Between Tumor Size and Survival in Non–Small-Cell Lung Cancer (NSCLC): An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Registry](https://scholariq.org/papers/relationship-between-tumor-size-and-survival-in-non-small-cell-lung-cancer-nsclc/)
- [Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics](https://scholariq.org/papers/immune-modulation-of-head-and-neck-squamous-cell-carcinoma-and-the-tumor/)
- [Clinicopathologic and molecular characteristics of EGFR-mutant lung adenocarcinomas that transform to small cell lung cancer after TKI therapy](https://scholariq.org/papers/clinicopathologic-and-molecular-characteristics-of-egfr-mutant-lung/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Head and Neck Cancer Studies](https://scholariq.org/topics/head-and-neck-cancer-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [UC San Diego Health System](https://scholariq.org/institutions/uc-san-diego-health-system/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.